Format

Send to

Choose Destination
Prog Cardiovasc Dis. 2016 Jan-Feb;58(4):425-33. doi: 10.1016/j.pcad.2015.09.006. Epub 2015 Oct 3.

Role of Vasodilator Testing in Pulmonary Hypertension.

Author information

1
Division of Cardiology, Department of Medicine, State University of New York Downstate Medical Center, NY, USA. Electronic address: abhisheksharma4mamc@gmail.com.
2
Department of Medicine, Maimonides Medical Center, NY, USA.
3
Department of Medicine, Einstein Medical Center, PA, USA.
4
Department of Medicine, Saint Peter's University Hospital, NJ, USA.
5
Division of Cardiology, Department of Medicine, Texas Tech University, El Paso, TX, USA.
6
Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY, USA.
7
Division of Cardiology, Department of Medicine and Department of Radiology, Columbia University Medical Center, New York, NY, USA.

Abstract

Pulmonary hypertension is clinically defined by a mean pulmonary artery (PA) pressure of 25mm Hg or more at rest, as measured by right heart catheterization. To identify patients who are likely to have a beneficial response to calcium channel blockers (CCBs) and therefore a better prognosis, acute vasodilator testing should be performed in patients in certain subsets of pulmonary arterial hypertension (PAH). A near normalization of pulmonary hemodynamics is needed before patients can be considered for therapy with CCBs. Intravenous adenosine, intravenous epoprostenol, inhaled nitric oxide, or inhaled iloprost are the standard agents used for vasoreactivity testing in patients with idiopathic PAH. In this review we describe the various aspects of vasodilator testing including the rationale, pathophysiology and agents used in the procedure.

KEYWORDS:

Pulmonary artery hypertension; Pulmonary hypertension; Vasodilator testing

PMID:
26434988
DOI:
10.1016/j.pcad.2015.09.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center